FII DATA FII Net (20-08-2024): -1457.96 DII Net (20-08-2024): +2252.10 #Investment #StockMarket #FinancialNews #TradingGloba FII DATA FII Net (20-08-2024): -1457.96 DII Net (20-08-2024): +2252.10 #Investment #StockMarket #FinancialNews #TradingGloba

Posted on by Raj Gaurav Rai

FII DATA FII Net (20-08-2024): -1457.96
DII Net (20-08-2024): +2252.10 #Investment #StockMarket #FinancialNews #TradingGloba FII DATA FII Net (20-08-2024): -1457.96
DII Net (20-08-2024): +2252.10 #Investment #StockMarket #FinancialNews #TradingGloba

Please follow and like us:
fb-share-icon
Tweet
Pin Share

Related Posts

Reliance Power LimitedReliance Power Limited is seeking shareholder approval through a postal ballot for two key resolutions:1) Introduction and Implementation of Reliance Power Employee Stock Option Scheme 2024, allowing the company to grant up to 22 crore stock options to employees, and2) Extending the scheme to employees of group companies, including subsidiaries, associates, and the holding company. E-voting is available from October 5th to November 3rd, 2024. #Financial #FinancialNews https://earnfree.in/latest Reliance Power LimitedReliance Power Limited is seeking shareholder approval through a postal ballot for two key resolutions:1) Introduction and Implementation of Reliance Power Employee Stock Option Scheme 2024, allowing the company to grant up to 22 crore stock options to employees, and2) Extending the scheme to employees of group companies, including subsidiaries, associates, and the holding company. E-voting is available from October 5th to November 3rd, 2024. #Financial #FinancialNews https://ift.tt/TMQ9r4i

Reliance Power Limited Reliance Power Limited is seeking shareholder approval through a postal ballot for two key resolutions: 1) Introduction and Implementation of Reliance Power […]

Aurobindo Pharma | USFDA Approval– Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray. – This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company

Aurobindo Pharma | USFDA Approval – Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate […]